// App-Quantinova.ai

989 : Regulatory T Cell Defects in SLE and Therapy with a Novel IL-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa

Researchers

Presenter

  • Nandita Sarkar

Principal Investigators

  • Xuguang Hu

  • Nadia Tchao

  • Richard Furie

  • Alan Kivitz

  • Stanley B Cohen

  • Kevin Gorski

Medical Centers

  • Northwell Health, Great Neck, NY

  • Metroplax Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

  • Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, United States

Locations

  • United Kingdom

  • United States

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Interleukin 2 Receptor Subunit Alpha

  • Cluster of Differentiation 2AP

  • Cluster of Differentiation 4

  • Interleukin-2

  • Regulatory T cells

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacodynamics

  • Multiple Ascending Dose

  • Cohort

Phase

  • I

Study Id's

  • NCT03451422

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved